BRPI0012138B8 - conjugado, composição que compreende conjugados, composição farmacêutica, uso de um conjugado ou uma composição e processo para a preparação de um conjugado ou uma composição - Google Patents

conjugado, composição que compreende conjugados, composição farmacêutica, uso de um conjugado ou uma composição e processo para a preparação de um conjugado ou uma composição

Info

Publication number
BRPI0012138B8
BRPI0012138B8 BRPI0012138A BR0012138A BRPI0012138B8 BR PI0012138 B8 BRPI0012138 B8 BR PI0012138B8 BR PI0012138 A BRPI0012138 A BR PI0012138A BR 0012138 A BR0012138 A BR 0012138A BR PI0012138 B8 BRPI0012138 B8 BR PI0012138B8
Authority
BR
Brazil
Prior art keywords
composition
conjugate
conjugates
kilodaltons
glycoprotein
Prior art date
Application number
BRPI0012138A
Other languages
English (en)
Other versions
BR0012138A (pt
BRPI0012138B1 (pt
Inventor
Hilger Bernd
Josel Hans-Peter
Burg Josef
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0012138A publication Critical patent/BR0012138A/pt
Publication of BRPI0012138B1 publication Critical patent/BRPI0012138B1/pt
Publication of BRPI0012138B8 publication Critical patent/BRPI0012138B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"<um>conjugado, composição que compreende conjugados, composição farmacêutica, utilização de um conjugado ou uma composição, processo para o tratamento profilático e/ou terapêutico de distúrbios e processo para a preparação de um conjugado ou composição<mv>". expõem-se conjugados de glicoproteína de eritropoietina, os ditos conjugados compreendendo uma glicoproteína de eritropoietina que é dotada de pelo menos um grupo amino livre e tendo a atividade biológica in vivo de fazer com que as células da medula óssea aumentem a produção de reticulócitos e de células vermelhas do sangue e selecionado a partir do grupo que consiste de eritropoietina humana e seus análogos que têm a estrutura principal da eritropoietina humana modificada pela adição de 1 a 6 locais de glicosilação ou pela reordenação de pelo menos um local de glicosilação; sendo a dita glicoproteína ligada covalentemente para formar de um a três grupos alcoxila poli(etileno glicol) inferior, sendo cada um dos grupos de poli(etileno glicol) ligado covalentemente à glicoproteína por intermédio de um ligante da fórmula -c(o)-x-s-y- com o c(o) do ligante formando uma aglutinação de amida com um dos ditos amino grupos, em que x e y são tais como definidos na descrição e reivindicações, o peso molecular médio de cada metade de poli(etileno glicol) varia entre cerca de 20 quilodaltons até cerca de 40 quilodaltons, e o peso molecular do conjugado varia entre cerca de 51 quilodaltons até cerca de 175 quilodaltons.
BRPI0012138A 1999-07-02 2000-06-28 conjugado, composição que compreende conjugados, composição farmacêutica, uso de um conjugado ou uma composição e processo para a preparação de um conjugado ou uma composição BRPI0012138B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14224399P 1999-07-02 1999-07-02
US14745299P 1999-08-05 1999-08-05
US15145499P 1999-08-30 1999-08-30
PCT/EP2000/006009 WO2001002017A2 (en) 1999-07-02 2000-06-28 Erythropoietin conjugates with polyethylenglycol

Publications (3)

Publication Number Publication Date
BR0012138A BR0012138A (pt) 2002-05-07
BRPI0012138B1 BRPI0012138B1 (pt) 2015-09-15
BRPI0012138B8 true BRPI0012138B8 (pt) 2021-05-25

Family

ID=27385779

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0012138A BRPI0012138B8 (pt) 1999-07-02 2000-06-28 conjugado, composição que compreende conjugados, composição farmacêutica, uso de um conjugado ou uma composição e processo para a preparação de um conjugado ou uma composição

Country Status (33)

Country Link
US (1) US6340742B1 (pt)
EP (1) EP1196443B1 (pt)
JP (1) JP4190184B2 (pt)
KR (1) KR100510624B1 (pt)
CN (1) CN1194014C (pt)
AR (1) AR024879A1 (pt)
AT (1) ATE267840T1 (pt)
AU (1) AU768452B2 (pt)
BR (1) BRPI0012138B8 (pt)
CA (1) CA2378533C (pt)
CO (1) CO5180621A1 (pt)
CZ (1) CZ301833B6 (pt)
DE (1) DE60011087T2 (pt)
DK (1) DK1196443T3 (pt)
ES (1) ES2220501T3 (pt)
GC (1) GC0000196A (pt)
HK (1) HK1047597B (pt)
HR (1) HRP20010966B1 (pt)
HU (1) HU228478B1 (pt)
IL (2) IL146956A0 (pt)
JO (1) JO2291B1 (pt)
MA (1) MA26806A1 (pt)
MX (1) MXPA01012974A (pt)
MY (1) MY126776A (pt)
NO (1) NO20016304L (pt)
NZ (1) NZ516170A (pt)
PE (1) PE20010288A1 (pt)
PL (1) PL201754B1 (pt)
PT (1) PT1196443E (pt)
RS (1) RS50117B (pt)
TR (1) TR200103782T2 (pt)
TW (1) TWI266637B (pt)
WO (1) WO2001002017A2 (pt)

Families Citing this family (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DK1037927T3 (da) 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
BR9909583A (pt) * 1998-04-15 2002-01-15 Lexigen Pharm Corp Aumento da resposta imune mediado por uma proteìna de fusão anticorpo-citocina por co-administração com inibidor de angiogênese
US7304150B1 (en) * 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
ATE514729T1 (de) 1999-02-01 2011-07-15 Eidgenoess Tech Hochschule Biomaterialien die durch nukleophile reaktion auf konjugierten ungesättigten gruppen addiert sind
US6958212B1 (en) 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
CA2380331C (en) * 1999-08-09 2012-11-20 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2001266557A1 (en) * 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
ATE291436T2 (de) * 2000-05-15 2005-04-15 Hoffmann La Roche Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
EP1292709B1 (en) * 2000-06-02 2012-01-18 Eidgenössische Technische Hochschule Zürich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
CN1270775C (zh) * 2000-06-29 2006-08-23 默克专利有限公司 通过与免疫细胞因子摄入促进剂联合治疗来增强抗体－细胞因子融合蛋白介导的免疫反应
WO2002032957A1 (fr) * 2000-10-16 2002-04-25 Chugai Seiyaku Kabushiki Kaisha Erythropoietine modifiee par peg
AU2002245205B2 (en) 2000-10-19 2007-07-19 Ecole Polytechnique Federale De Lausanne Block copolymers for multifunctional self-assembled systems
KR101229995B1 (ko) * 2000-12-11 2013-02-06 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
DE60117919T2 (de) * 2000-12-11 2006-12-14 Cheil Jedang Corp. Fusionsprotein mit verbesserter in vivo erythropoietinwirkung
CA2431964C (en) * 2000-12-20 2013-09-10 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
DE60144439D1 (de) * 2000-12-20 2011-05-26 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
DK1366067T3 (da) * 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
CA2446087C (en) * 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
CA2446739A1 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US6930086B2 (en) * 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
ES2516041T3 (es) * 2001-10-10 2014-10-30 Ratiopharm Gmbh Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH)
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
KR100480423B1 (ko) * 2001-12-04 2005-04-06 선바이오(주) 에리트로포이에틴과 폴리에틸렌글리콜 유도체의 배합체
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
CA3094774A1 (en) * 2001-12-06 2003-07-03 Fibrogen, Inc. Use of hif prolyl hydroxylase inhibitors for treating neurological disorders
AU2002351746A1 (en) * 2001-12-21 2003-07-15 Maxygen Aps Erythropoietin conjugates
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
WO2003059934A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7300915B2 (en) 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
WO2004013164A1 (en) * 2002-07-24 2004-02-12 F. Hoffmann-La Roche Ag Pegylated t20 polypeptide
EP1546193A1 (en) * 2002-07-24 2005-06-29 F. Hoffmann-La Roche Ag Pegylated t1249 polypeptide
BR0312863B1 (pt) * 2002-07-24 2013-02-05 derivados de aldeÍdo de polietileno glicol e processo de produÇço dos mesmos.
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
WO2005025606A1 (en) * 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
EP1545586A4 (en) * 2002-09-09 2007-09-26 Warren Pharmaceuticals Inc LONG-ACTING ERYTHROPOIETINES THAT MAINTAIN THE PROTECTIVE ACTIVITY OF THE TISSUE OF ENDOGENEURY ERYTHROPOIETIN
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
ATE471946T1 (de) * 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
WO2004060300A2 (en) * 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
BR0317742A (pt) * 2002-12-26 2005-11-22 Mountain View Pharmaceuticals Conjugados poliméricos de interferon-beta com potência biológica aumentada
EP1616003A4 (en) * 2002-12-30 2007-06-20 Gryphon Therapeutics Inc WATER-SOLUBLE THIOESTER AND SELENOESTER COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
ATE399185T1 (de) † 2002-12-31 2008-07-15 Nektar Therapeutics Al Corp Maleinsäureamid polymerderivate und ihre biokonjugate
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
SG177008A1 (en) * 2003-03-05 2012-01-30 Halozyme Inc Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
KR20060003862A (ko) 2003-03-14 2006-01-11 네오스 테크놀로지스, 인크. 수용성분기폴리머 및 그 접합체
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
CA2520875A1 (en) * 2003-03-31 2004-10-21 Xencor, Inc. Methods for rational pegylation of proteins
MXPA05010773A (es) * 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP1626983B8 (en) * 2003-05-12 2010-12-22 Affymax, Inc. Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof
PT1629007E (pt) * 2003-05-12 2009-05-06 Affymax Inc Péptidos novos que se ligam ao receptor da eritropoietina
WO2004101611A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Peptides that bind to the erythropoietin receptor
CA2525399A1 (en) 2003-05-12 2004-11-25 Affymax, Inc. Novel spacer moiety for poly(ethylene glycol)-modified peptide-based co mpounds
US7074755B2 (en) 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
JP2007537986A (ja) * 2003-05-30 2007-12-27 セントカー・インコーポレーテツド トランスグルタミナーゼを用いる新規なエリトロポエチン複合体の形成
EP1491554A1 (en) * 2003-06-23 2004-12-29 CONARIS research institute AG PEGylated soluble gp130-dimers useful as a medicament
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
MXPA06003234A (es) * 2003-09-29 2006-06-08 Warren Pharmaceuticals Inc Citosinas protectoras de los tejidos para el tratamiento y prevencion de la sepsis y la formacion de adhesiones.
EP1675871A2 (en) 2003-10-10 2006-07-05 Xencor Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
JP4870569B2 (ja) * 2003-11-13 2012-02-08 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
AU2004293103C1 (en) * 2003-11-24 2010-12-02 Ratiopharm Gmbh Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
AU2004298996A1 (en) 2003-12-10 2005-06-30 Nektar Therapeutics Al, Corporation Compositions comprising two different populations of polymer-active agent conjugates
EP1696947B1 (en) 2003-12-19 2014-02-26 F.Hoffmann-La Roche Ag Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases
CA2550301A1 (en) 2003-12-30 2005-07-14 Bionethos Holding Gmbh Tissue regeneration method
KR20060124656A (ko) * 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
BRPI0506741A (pt) 2004-01-08 2007-05-15 Neose Technologies Inc glicosilação de peptìdeos ligados a o
CN101001866A (zh) * 2004-02-02 2007-07-18 Ambrx公司 经修饰的人类干扰素多肽和其用途
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
EP1737888A2 (en) * 2004-04-23 2007-01-03 Cambridge Antibody Technology LTD Erythropoietin protein variants
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
JP5948627B2 (ja) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化
US20090118195A1 (en) * 2004-11-10 2009-05-07 Hans-Georg Frank Molecules Which Promote Hematopoiesis
US7589063B2 (en) * 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
CA2587382A1 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
EP1858543B1 (en) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylated granulocyte colony stimulating factor
EP1848461A2 (en) * 2005-02-16 2007-10-31 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
US20070154992A1 (en) * 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP2377884A1 (en) 2005-05-10 2011-10-19 Neoloch Aps Neuritogenic peptides
US9988427B2 (en) 2005-05-13 2018-06-05 Charite Universitaetsmedizen-Berlin Erythropoietin variants
JP5216580B2 (ja) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
EP2298829B1 (en) 2005-05-31 2017-09-20 École Polytechnique Fédérale de Lausanne (EPFL) Triblock copolymers for cytoplasmic delivery of gene-based drugs
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP1907417A2 (en) * 2005-06-23 2008-04-09 AplaGen GmbH Supravalent compounds
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
EP2380435B1 (en) * 2005-08-31 2016-05-25 Kaneka Corporation Feline-derived erythropoietin and method for production thereof
JP5198747B2 (ja) * 2005-08-31 2013-05-15 株式会社カネカ ネコ由来タンパク質のコード配列を含む外来性遺伝子を含むトランスジェニック鳥類およびその作製法
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
US20070092486A1 (en) * 2005-10-21 2007-04-26 Avigenics, Inc. Glycolated and glycosylated poultry derived therapeutic proteins
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US7553941B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
CN101062407A (zh) 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 促红细胞生成素在预防或治疗视网膜损伤中的用途
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
ES2529234T3 (es) 2006-08-04 2015-02-18 Prolong Pharmaceuticals, LLC Eritropoyetina modificada
EP2054521A4 (en) * 2006-10-03 2012-12-19 Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
KR101556248B1 (ko) * 2006-10-04 2015-09-30 노보 노르디스크 에이/에스 글리세롤이 연결된 페길화된 당 및 글리코펩티드
US20080083154A1 (en) * 2006-10-05 2008-04-10 Timothy M Gregory Bait retention fish hook
WO2008057537A2 (en) * 2006-11-08 2008-05-15 Maine Medical Center Research System and method for identifying erythropoietin-responsive genes
DK2081956T3 (da) 2006-11-13 2013-06-24 Charite Universitaetsmedizin FREMGANGSMÅDE TIL CELLEDYRKNING OG FREMGANGSMÅDE TIL BEHANDLING OMFATTENDE EN vEPO-PROTEINVARIANT
RS52845B (en) 2007-04-03 2013-12-31 Biogenerix Ag TREATMENT PROCEDURES USING GLYCOPEGILATED G-CSF
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
EP2018835B1 (de) 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
CL2008002053A1 (es) 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
AR067536A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
US20090022720A1 (en) 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
CN101381412B (zh) * 2007-09-30 2012-02-22 深圳赛保尔生物药业有限公司 聚合物/重组人促红素偶联物
CN101455844B (zh) * 2007-12-10 2011-09-14 江苏豪森药业股份有限公司 聚乙二醇化促红细胞生成素偶联物和其制备方法与用途
JP5647899B2 (ja) * 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
US8101706B2 (en) * 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
EP2669313B1 (en) 2008-01-11 2016-03-23 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
JP5702150B2 (ja) 2008-02-08 2015-04-15 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾されているレプチンポリペプチドおよびそれらの使用
EP2257311B1 (en) 2008-02-27 2014-04-16 Novo Nordisk A/S Conjugated factor viii molecules
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
EP3192525A1 (en) 2008-04-14 2017-07-19 Halozyme, Inc. Modified hyaluronidases for use in treating hyaluronan-associated diseases and conditions
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
PT3050576T (pt) 2008-04-29 2021-06-01 Ascendis Pharma Growth Disorders Div A/S Compostos recombinantes e peguilados da hormona de crescimento humana
EP2161031A1 (en) 2008-09-05 2010-03-10 SuppreMol GmbH Fc gamma receptor for the treatment of B cell mediated multiple sclerosis
CN107022020A (zh) 2008-09-26 2017-08-08 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
JP5814793B2 (ja) 2008-11-25 2015-11-17 エコール ポリテクニク フェデラル ド ローザンヌ（エーペーエフエル） ブロックコポリマーおよびその使用
EP3037529B1 (en) 2008-12-09 2019-03-27 Halozyme, Inc. Extended soluble ph20 polypeptides and uses thereof
GB0922354D0 (en) 2009-12-21 2010-02-03 Polytherics Ltd Novel polymer conjugates
MX347291B (es) 2009-03-20 2017-04-17 Amgen Inc Inmunoglobulinas portadoras y usos de las mismas.
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
MX2012003282A (es) 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
ES2632164T3 (es) 2010-07-06 2017-09-11 Augustinus Bader Aplicación tópica de eritropoyetina para uso en el tratamiento de lesiones de la córnea
JP2013540103A (ja) 2010-07-20 2013-10-31 ハロザイム インコーポレイテッド 抗ヒアルロナン剤の投与に関連する有害副作用の処置
JP5735650B2 (ja) 2010-09-14 2015-06-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｐｅｇ化エリスロポエチンを精製するための方法
EA201370076A1 (ru) 2010-09-22 2013-08-30 Амген Инк. Иммуноглобулины-переносчики и их применение
CN102453087B (zh) * 2010-10-22 2013-12-25 广东赛保尔生物医药技术有限公司 一种单取代peg-epo的纯化及制备方法
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
JP5890516B2 (ja) 2011-06-17 2016-03-22 ハロザイム インコーポレイテッド ヒアルロナン分解酵素を用いる連続的皮下インスリン注入方法
WO2013040501A1 (en) 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
JP6162707B2 (ja) 2011-10-24 2017-07-12 ハロザイム インコーポレイテッド 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法
SG11201403714TA (en) 2011-12-30 2014-07-30 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof
SI2833905T1 (en) 2012-04-04 2018-08-31 Halozyme, Inc. Combination therapy with hyaluronidase and tumane-directed taxane
MY167814A (en) 2012-04-19 2018-09-26 Opko Biologics Ltd Long-acting oxyntomodulin variants and methods of producing same
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
BR122020018510B1 (pt) 2012-11-20 2023-03-14 Opko Biologics Ltd Método para aumentar incrementalmente o tamanho hidrodinâmico de um fator de coagulação ativado viia
EP3524691A1 (en) 2012-12-07 2019-08-14 SuppreMol GmbH Stratification and treatment of patients of idiopathic thrombocytopenic purpura
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
WO2015013510A1 (en) 2013-07-25 2015-01-29 Ecole Polytechnique Federale De Lausanne Epfl High aspect ratio nanofibril materials
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3186281B1 (en) 2014-08-28 2019-04-10 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
EA201700181A1 (ru) 2014-10-14 2017-09-29 Галозим, Инк. Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
ES2893616T3 (es) 2015-06-19 2022-02-09 Opko Biologics Ltd Factores de coagulación de acción prolongada y métodos para la producción de los mismos
AR107823A1 (es) * 2016-03-07 2018-06-06 Hanmi Pharm Ind Co Ltd Derivados de polietilenglicol y uso de los mismos
CN105820232B (zh) * 2016-04-08 2019-05-17 昂德生物药业有限公司 单修饰聚乙二醇重组人促红素的制备方法及其制品和应用
AU2017296352A1 (en) 2016-07-11 2019-02-21 Opko Biologics Ltd. Long-acting coagulation factor VII and methods of producing same
CA3027143A1 (en) * 2016-07-15 2018-01-18 F. Hoffmann-La Roche Ag Method for purifying pegylated erythropoietin
WO2018132768A1 (en) 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
KR102268647B1 (ko) 2017-06-12 2021-06-23 한국코러스 주식회사 안정성이 향상된 에리스로포이에틴 조성물 및 이의 제조방법
KR20200030063A (ko) 2017-06-22 2020-03-19 카탈리스트 바이오사이언시즈, 인코포레이티드 변형된 막 유형 세린 프로테아제 １(ｍｔｓｐ－１) 폴리펩티드 및 사용 방법
CN111727063A (zh) * 2017-12-29 2020-09-29 豪夫迈·罗氏有限公司 用于提供聚乙二醇化蛋白质组合物的方法
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
MX2021007843A (es) 2018-12-28 2021-08-11 Vertex Pharma Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso.
CN111375068B (zh) * 2018-12-29 2024-04-16 江苏豪森药业集团有限公司 聚乙二醇化多肽药物的制备方法
US20220387609A1 (en) * 2019-03-29 2022-12-08 Nof Corporation Branched degradable polyethylene glycol binder
EP4219537A1 (en) * 2020-09-22 2023-08-02 Jecho Laboratories, Inc. Glycosylation-modified erythopoietin and use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4677195A (en) 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
EP0318487B1 (en) 1986-08-04 1993-10-13 The University Of New South Wales Serum free tissue culture medium containing polymeric cell-protective agent
US4954437A (en) 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
EP0343635B1 (en) 1988-05-25 1994-08-24 Teijin Limited Process for continuously culturing adherent animal cells
US6225449B1 (en) * 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
DE3924705A1 (de) 1989-07-26 1991-01-31 Boehringer Mannheim Gmbh Heterobifunktionelle verbindungen
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
IL110669A (en) * 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
ES2174915T3 (es) 1993-11-10 2002-11-16 Enzon Inc Productos de conjugacion mejorados de un interferon con un polimero.
IL112583A0 (en) 1994-02-08 1995-05-26 Amgen Inc Oral delivery of chemically modified proteins
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
ES2093593T1 (es) 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
IL118201A (en) 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
US6025324A (en) 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions

Also Published As

Publication number Publication date
AU6429900A (en) 2001-01-22
PL356065A1 (en) 2004-06-14
GC0000196A (en) 2006-03-29
HRP20010966A2 (en) 2005-02-28
CN1194014C (zh) 2005-03-23
CN1359392A (zh) 2002-07-17
AR024879A1 (es) 2002-10-30
CA2378533C (en) 2006-02-14
MY126776A (en) 2006-10-31
HRP20010966B1 (en) 2006-02-28
IL146956A0 (en) 2002-08-14
WO2001002017A3 (en) 2001-08-09
JO2291B1 (en) 2005-09-12
KR100510624B1 (ko) 2005-08-31
TWI266637B (en) 2006-11-21
BR0012138A (pt) 2002-05-07
PL201754B1 (pl) 2009-05-29
DE60011087T2 (de) 2005-06-16
MA26806A1 (fr) 2004-12-20
BRPI0012138B1 (pt) 2015-09-15
EP1196443A2 (en) 2002-04-17
IL146956A (en) 2006-10-31
HUP0201971A2 (en) 2002-09-28
TR200103782T2 (tr) 2002-05-21
RS50117B (sr) 2009-03-25
JP4190184B2 (ja) 2008-12-03
KR20020026514A (ko) 2002-04-10
HU228478B1 (en) 2013-03-28
AU768452B2 (en) 2003-12-11
WO2001002017A2 (en) 2001-01-11
CZ301833B6 (cs) 2010-07-07
HK1047597B (zh) 2005-08-12
US6340742B1 (en) 2002-01-22
HUP0201971A3 (en) 2010-01-28
YU89901A (sh) 2004-05-12
NO20016304L (no) 2002-02-19
ATE267840T1 (de) 2004-06-15
JP2003503464A (ja) 2003-01-28
DE60011087D1 (de) 2004-07-01
CZ20014682A3 (cs) 2002-11-13
PE20010288A1 (es) 2001-03-07
ES2220501T3 (es) 2004-12-16
PT1196443E (pt) 2004-09-30
NO20016304D0 (no) 2001-12-21
DK1196443T3 (da) 2004-10-04
NZ516170A (en) 2004-02-27
CA2378533A1 (en) 2001-01-11
HK1047597A1 (en) 2003-02-28
MXPA01012974A (es) 2002-07-30
EP1196443B1 (en) 2004-05-26
CO5180621A1 (es) 2002-07-30

Similar Documents

Publication Publication Date Title
BRPI0012138B8 (pt) conjugado, composição que compreende conjugados, composição farmacêutica, uso de um conjugado ou uma composição e processo para a preparação de um conjugado ou uma composição
BRPI0002276B8 (pt) conjugado, composição que compreende conjugados, composição farmacêutica, utilização de um conjugado ou composição e processso para a preparação de compostos
JP2859105B2 (ja) インターフエロン抱合体
BR0116381A (pt) Conjugado, composição farmacêutica que compreende o mesmo e sua utilização, processo para o tratamento profilático e/ou terapêutico de distúrbios, processo para a preparação de um conjugado, compostos e glicoproteìnas de eritropoetina
RU2005119649A (ru) Новое применение эритропоэтина при сердечных заболеваниях
BR0207576A (pt) Variante glicosilada de um polipeptìdeo de interferon beta precursor (ifnb), processos de aumentar a glicosilação in vivo de uma molécula de ifnb precursora, de produzir uma molécula de ifnb glicosilada, para preparar uma variante conjugada e de tratar um mamìfero com esclerose múltiplam composição farmacêutica, molécula de ifnb variante, sequência de nucleotìdeo, vetor de expressão, célula hospedeira de glicosilação conjugado, e, uso de um conjugado
BRPI0314831B8 (pt) composições farmacêuticas e composição de lipossoma peg compreendendo um conjugado, seus métodos de produção, kit e usos terapêuticos das ditas composições
US20020058611A1 (en) Carrier for in vivo delivery of a therapeutic agent
RU2001112488A (ru) Поперечносшитые гиалуроновые кислоты и их применение в медицине
AR041061A1 (es) Uso de la eritropoyetina en pacientes con diabetes
BR0013638A (pt) Novas moléculas semelhantes a interferon beta
BR0206852A (pt) Conjugados de polìmero de neublastina e métodos para uso dos mesmos
EP1382352A1 (de) Bisacyloxypropylcystein-Konjugate und deren Verwendung
EP0066379A2 (en) Composition for combating herpes virus
RU2002102232A (ru) Конъюгаты эритропоэтина и полиэтиленгликоля (второе название &#34;Производные эритропоэтина&#34;)
UY26229A1 (es) Derivados de la eritopoyetina
Malsch et al. Semisynthesis and analysis of lipophilically modified unfractionated and low molecular mass heparins
JO2257B1 (en) Erythropoietin derivatives
CN102964442A (zh) 一种聚乙二醇同神经生长因子结合物的制备方法
McNicol Proteoglycans from the meniscus of the human knee
ECSP003557A (es) Derivados de eritropoyetina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A61K 47/48

Ipc: C07K 14/505 (2006.01), A61K 47/48 (2006.01)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2015, OBSERVADAS AS CONDICOES LEGAIS.

B15K Others concerning applications: alteration of classification

Ipc: C07K 14/505 (2006.01), A61K 47/60 (2017.01), A61K

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/06/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 28/06/2020